Short answer
Theravance Biopharma, Inc. (TBPH) filed an 8-K current report with the SEC on June 12, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). 91.4% shareholder participation established quorum at the June 12, 2026 annual meeting.
Theravance Biopharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 91.4% shareholder participation established quorum at the June 12, 2026 annual meeting
- All six director nominees elected through 2027, with 41,936,019–42,725,649 votes supporting each
- Ernst & Young LLP auditor appointment ratified by 46,471,340 votes, supporting audit continuity
- Executive compensation advisory vote approved with 42,631,324 votes, indicating shareholder support for pay practices
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Theravance Biopharma, Inc. 8-K filings
Get the next TBPH 8-K as it lands
Follow TBPH for push alerts, or ask the research agent what this filing means.